VentiRx Pharmaceuticals Announces the Completion of Patient Enrollment in Randomized, Placebo-controlled Phase 2 Trial of VTX

  VentiRx Pharmaceuticals Announces the Completion of Patient Enrollment in
 Randomized, Placebo-controlled Phase 2 Trial of VTX-2337 in Combination with
     Pegylated-Liposomal Doxorubicin in Platinum-resistant Ovarian Cancer

Company also announces designation of Orphan Drug Status by FDA for VTX-2337
in Ovarian Cancer

PR Newswire

SEATTLE, April 17, 2014

SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today
announced that enrollment has been completed in GOG-3003 (NCT01666444), a
randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with
Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent
epithelial ovarian, fallopian tube or primary peritoneal cancer who have
failed prior platinum-based chemotherapy.

VentiRx Pharmaceuticals Logo

VTX-2337 is a novel, investigational small molecule that targets Toll-like
receptor 8 (TLR8). PLD is the standard of care for the treatment of
platinum-resistant ovarian cancer and encouraging data have been reported with
PLD and VTX-2337 in a recently completed Phase 1b study (GOG-9925,
NCT01294293).

The Phase 2 GOG-3003 study has reached its target enrollment with more than
290 patients randomized at over 85 institutions throughout North America. The
study is being performed in collaboration with the Gynecologic Oncology Group
(GOG) Partners Program. Women were randomized to receive PLD plus VTX-2337 or
PLD plus placebo. The primary endpoint of the trial is overall survival.

"There are limited treatments available for women with platinum-resistant
ovarian cancer and completion of this study brings us closer to validating new
cancer immunotherapies like VTX‑2337 as a new treatment option. We are hopeful
that this novel approach of combining a selective modulator of the innate
immune system with chemotherapy may extend survival for woman with ovarian
cancer," said Bradley Monk, M.D., University of Arizona Cancer Center at St.
Joseph's Hospital and Medical Center, chair of the study.

"Completion of enrollment in the large, randomized GOG-3003 trial and receipt
of orphan drug designation for VTX-2337 in ovarian cancer are important
milestones for VentiRx in the development of our novel immunomodulator
VTX-2337," said Robert Hershberg, M.D., Ph.D., President and Chief Executive
Officer of VentiRx. "We appreciate the tremendous effort of the GOG in the
enrollment of this trial ahead of schedule, and look forward to the
event-driven analysis in late 2015."

GOG-3003 is one of two Phase 2 clinical trials of VTX-2337 currently underway.
The second trial, called Active8, is a company-sponsored, randomized, Phase 2
placebo-controlled trial in patients with locally advanced and metastatic
squamous cell carcinoma of the head and neck. The study is evaluating VTX-2337
in combination with cetuximab and chemotherapy vs. cetuximab and chemotherapy
alone. Progression-free survival is the primary endpoint. The Active8 trial is
currently enrolling patients in the U.S. More information on this trial is
available at clinicaltrials.gov (NCT01836029).

The company also announced that the U.S. Food and Drug Administration (FDA)
granted Orphan Drug designation to VTX-2337 for the treatment of ovarian
cancer. Orphan Drug Designation is granted by the FDA Office of Orphan Drug
Products and is given to drugs that meet certain criteria and are designed to
treat a rare disease or condition affecting fewer than 200,000 people in the
U.S.

About VTX-2337

VTX-2337 is a novel Toll-like Receptor 8 (TLR8) agonist that directly
activates multiple components of the innate immune system. This includes
activation of human myeloid dendritic cells (mDCs), monocytes and natural
killer (NK) cells resulting in the production of high levels of mediators
known to orchestrate the integration of innate and adaptive antitumor
responses.

Results from preclinical models suggest that combining VTX-2337 with PLD may
provide a synergistic effect in stimulating a variety of immune pathways
associated with antitumor activity. A recently completed Phase 1 trial in this
same study population demonstrated that the combination was safe and
well-tolerated.

About Ovarian Cancer

There will be an estimated 22,240 new cases of ovarian cancer in the United
States and over 40,000 new cases in the European Union in 2014. Ovarian cancer
is one of the most lethal gynecologic cancers. Women with recurrent or
persistent ovarian cancer recur within 6-12 months of completion with a
platinum-containing regimen and there remains a high unmet need for improved
treatment options.

About The Gynecologic Oncology Group

The GOG is a national non-profit organization dedicated to clinical research
in the field of gynecologic cancer. The purpose of the GOG is to improve the
treatment of gynecologic cancer. These goals are addressed through research
encompassing surgery, radiation therapy, chemotherapy, pathology, immunology
and/or gynecologic nursing. To promote this mission, the GOG receives support
from the National Cancer Institute (NCI) of the National Institutes for
Health. The GOG has a history of establishing treatment standards for ovarian
cancer, demonstrating improved survival with platinum therapy in the early
1980s and again with the combination of paclitaxel and platinum in the
mid-1990s.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company
committed to the development and commercialization of novel Toll-like receptor
8 (TLR8) immunotherapies for the treatment of cancer, respiratory and
inflammatory diseases. The Company's lead product candidate is VTX-2337, a
small molecule TLR8 agonist for the treatment of cancer. VentiRx has an
exclusive, world-wide collaboration with Celgene Corporation for VTX-2337.
VentiRx is a privately held organization based in Seattle, Washington. For
additional information, please visit www.ventirx.com.

Logo- http://photos.prnewswire.com/prnh/20120123/SF39404LOGO

SOURCE VentiRx

Website: http://www.ventirx.com
Contact: Robert Hershberg, M.D., Ph.D., Chief Executive Officer VentiRx
Pharmaceuticals, Inc., (206) 689-2269, rhershberg@ventirx.com; Katie Fanning,
Vice President, Business Development, (206) 973-1586, kfanning@ventirx.com
 
Press spacebar to pause and continue. Press esc to stop.